For readers interested in discovering drugs that target regulated non-apoptotic cell death pathways including necroptosis, pyroptosis and ferroptosis, here's a comprehensive recent review bit.ly/3OMtxwU rdcu.be/dFLCa

RIPK3 inhibitor prevents lung damage in severe influenza infection bit.ly/3w8AqC5

Our latest research highlight covers a paper in Nature on a novel inhibitor of RIPK3 that blocks necroptosis and reduces mortality in mice with influenza

For readers interested in mRNA therapeutics, this recent review covers levers for their design, focusing on the interplay between mRNA sequence and structure, and how these parameters affect mRNA function and stability bit.ly/3uAigrL rdcu.be/dFDJG

mRNA therapy shows promise for metabolic disorder bit.ly/4b86qFo

Our latest research highlight covers a pioneering clinical trial for an mRNA therapeutic for the rare metabolic disorder propionic acidaemia

Strategies to improve the systemic distribution of siRNA drugs and promote efficacy in tissues beyond the liver include conjugation to lipids or targeting entities such as antibodies - find out more in this Review bit.ly/3vGBPzv

I had the pleasure of speaking with Nature Reviews Drug Discovery about one of the topics I’m most passionate about: the potential of sequential immunotherapy to treat autoimmune diseases. We also discussed genetics and its role in causal human biology. nature.com/articles/d4157…

Interested in mRNA-based therapies and vaccines? This Review in the April issue discusses strategies to reduce the risk of safety issues with such products, including the use of next-generation screening tools bit.ly/48GuO03 bit.ly/48GuO03

RNA-editing drugs advance into clinical trials bit.ly/445OqZV

ADAR-based editors that can change the mRNA code offer new opportunities in both rare genetic diseases and common complex ones. Find out more in this news article published today

Three-step cures for autoimmune diseases? bit.ly/4aUCfkP

Robert Plenge, head of Research at Bristol Myers Squibb, discusses his vision of sequential immunotherapy for autoimmune diseases such as lupus and multiple sclerosis in this new interview

Glad to share our latest Nature Reviews Drug Discovery piece on targeting #immunogeniccelldeath in #cancer , available at rdcu.be/dEMqs Thanks to Emma Guilbaud and others #offtwitter . Weill Cornell Medicine Weill Cornell Medicine Meyer Cancer Center WCM Englander Institute for Precision Medicine Centre de Recherche des Cordeliers #WCMRadonc ROBIN ImmunoRad Center

The antibody–drug conjugate landscape
bit.ly/3vKHoNB

This new analysis investigates innovation in the clinical pipeline for antibody–drug conjugates across five design levers: target, payload mechanism of action, antibody, linker and conjugation method

Targeting immunogenic cell stress and death for cancer therapy bit.ly/43XBsx6

This new Review covers immunogenic cell death (ICD) mechanisms that can be harnessed for cancer therapy and countermeasures against the ways that cancer cells subvert ICD induction by drugs

FDA new drug approvals in Q1 2024 bit.ly/3xziIbc
10 new drugs were approved, including first-in-class drugs for NASH/MASH, pulmonary arterial hypertension, Duchenne muscular dystrophy and PNH. Find out more in this new analysis from Paul Verdin Evaluate Pharma

For readers interested in therapeutic strategies for Duchenne muscular dystrophy, including exon-skipping oligonucleotides, gene therapies and HDAC inhibitors, here's a comprehensive bit.ly/3r48QU2 rdcu.be/dEtf2

FDA approves an HDAC inhibitor for Duchenne muscular dystrophy bit.ly/3VUbKb2

For readers interested in bispecific antibodies for cancer therapy, this Review in the April issue covers bispecific T-cell and NK-cell engagers, tumour-targeted receptor agonists, checkpoint inhibitors and more bit.ly/3T7gZkH rdcu.be/dElGD #AACR24

Interested in membrane transporters? This review in the April issue from the International Transporter Consortium summarizes the current status of transporters in drug development and discusses implications for precision medicine bit.ly/4bbWwmY rdcu.be/dD7UR

Genome-editing medicinal products: the EMA perspective bit.ly/3J7hgzn

With the aim of aiding developers of genome-editing medicinal products, this article discusses insights the European Medicines Agency has gained from scientific advice procedures for such products

Our April issue is live! Read about the first drug for NASH/MASH, membrane transporters in drug development, strategies to the reduce the risk of mRNA drug toxicity, bispecific antibodies for cancer therapy and more here bit.ly/4cHYrAl

RNAi-based drug design: considerations and future directions bit.ly/3vGBPzv
This new review discusses key aspects of the design of therapeutic siRNAs, including chemistry, the application of informatics, delivery strategies and the importance of careful target selection